In Vivo Amyloid Imaging with PET in Frontotemporal Dementia

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2007 Sep 12

PMID 17846768

Citations 70

Authors

Henry Engler

Alexander Frizell Santillo

Shu Xia Wang

Maria Lindau

Irina Savitcheva

Agneta Nordberg

Lars Lannfelt

Bengt Langstrom

Lena Kilander

Affiliations

Soon will be listed here.

Abstract

Background: N-methyl[11C]2-(4'methylaminophenyl)-6-hydroxy-benzothiazole (PIB) is a positron emission tomography (PET) tracer with amyloid binding properties which allows in vivo measurement of cerebral amyloid load in Alzheimer's disease (AD). Frontotemporal dementia (FTD) is a syndrome that can be clinically difficult to distinguish from AD, but in FTD amyloid deposition is not a characteristic pathological finding.

Purpose: The aim of this study is to investigate PIB retention in FTD.

Methods: Ten patients with the diagnosis of FTD participated. The diagnosis was based on clinical and neuropsychological examination, computed tomography or magnetic resonance imaging scan, and PET with 18 Fluoro-2-deoxy-d-glucose (FDG). The PIB retention, measured in regions of interest, was normalised to a reference region (cerebellum). The results were compared with PIB retention data previously obtained from 17 AD patients with positive PIB retention and eight healthy controls (HC) with negative PIB retention. Statistical analysis was performed with a students t-test with significance level set to 0.00625 after Bonferroni correction.

Results: Eight FTD patients showed significantly lower PIB retention compared to AD in frontal (p < 0.0001), parietal (p < 0.0001), temporal (p = 0.0001), and occipital (p = 0.0003) cortices as well as in putamina (p < 0.0001). The PIB uptake in these FTD patients did not differ significantly from the HC in any region. However, two of the 10 FTD patients showed PIB retention similar to AD patients.

Conclusion: The majority of FTD patients displayed no PIB retention. Thus, PIB could potentially aid in differentiating between FTD and AD.

Citing Articles

Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.

Aye W, Stark M, Horne K, Livingston L, Grenfell S, Myall D Alzheimers Dement (Amst). 2024; 16(2):e12601.

PMID: 38912306 PMC: 11193095. DOI: 10.1002/dad2.12601.

Two decades of [C]PiB synthesis, 2003-2023: a review.

Myburgh P, Sai K Am J Nucl Med Mol Imaging. 2024; 14(1):48-62.

PMID: 38500746 PMC: 10944378.

Model-based whole-brain perturbational landscape of neurodegenerative diseases.

Sanz Perl Y, Fittipaldi S, Gonzalez Campo C, Moguilner S, Cruzat J, Fraile-Vazquez M Elife. 2023; 12.

PMID: 36995213 PMC: 10063230. DOI: 10.7554/eLife.83970.

The tauopathies: Neuroimaging characteristics and emerging experimental therapies.

Riley K, Graner B, Veronesi M J Neuroimaging. 2022; 32(4):565-581.

PMID: 35470528 PMC: 9545715. DOI: 10.1111/jon.13001.

Frontotemporal Dementias in Latin America: History, Epidemiology, Genetics, and Clinical Research.

Llibre-Guerra J, Behrens M, Hosogi M, Montero L, Torralva T, Custodio N Front Neurol. 2021; 12:710332.

PMID: 34552552 PMC: 8450529. DOI: 10.3389/fneur.2021.710332.

References

Lopresti B, Klunk W, Mathis C, Hoge J, Ziolko S, Lu X . Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005; 46(12):1959-72. View

Jeong Y, Cho S, Park J, Kang S, Lee J, Kang E . 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005; 46(2):233-9. View

PATLAK C, Blasberg R, Fenstermacher J . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3(1):1-7. DOI: 10.1038/jcbfm.1983.1. View

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I . Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006; 129(Pt 11):2856-66. DOI: 10.1093/brain/awl178. View

Klunk W, Wang Y, Huang G, Debnath M, Holt D, Shao L . The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003; 23(6):2086-92. PMC: 6741999. View

Knopman D, Parisi J, Salviati A, Floriach-Robert M, Boeve B, Ivnik R . Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003; 62(11):1087-95. DOI: 10.1093/jnen/62.11.1087. View

Kertesz A, McMonagle P, Blair M, Davidson W, Munoz D . The evolution and pathology of frontotemporal dementia. Brain. 2005; 128(Pt 9):1996-2005. DOI: 10.1093/brain/awh598. View

Hulette C, Welsh-Bohmer K, Murray M, Saunders A, Mash D, McIntyre L . Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998; 57(12):1168-74. DOI: 10.1097/00005072-199812000-00009. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

10.

Hodges J . Frontotemporal dementia (Pick's disease): clinical features and assessment. Neurology. 2001; 56(11 Suppl 4):S6-10. DOI: 10.1212/wnl.56.suppl_4.s6. View

11.

Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

12.

Litvan I, Agid Y, Sastry N, Jankovic J, Wenning G, Goetz C . What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology. 1997; 49(1):62-9. DOI: 10.1212/wnl.49.1.62. View

13.

Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D . Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3):306-19. DOI: 10.1002/ana.20009. View

14.

Price J, Klunk W, Lopresti B, Lu X, Hoge J, Ziolko S . Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005; 25(11):1528-47. DOI: 10.1038/sj.jcbfm.9600146. View

15.

Neary D, Snowden J, Gustafson L, Passant U, Stuss D, Black S . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998; 51(6):1546-54. DOI: 10.1212/wnl.51.6.1546. View

16.

Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Riemenschneider M, Forstl H . Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2006; 28(1):42-50. DOI: 10.1016/j.neurobiolaging.2005.11.002. View

17.

Kitagaki H, Mori E, Yamaji S, Ishii K, Hirono N, Kobashi S . Frontotemporal dementia and Alzheimer disease: evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. Radiology. 1998; 208(2):431-9. DOI: 10.1148/radiology.208.2.9680572. View

18.

Andersson J, Thurfjell L . Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr. 1997; 21(1):136-44. DOI: 10.1097/00004728-199701000-00027. View

19.

McKhann G, Albert M, Grossman M, Miller B, Dickson D, Trojanowski J . Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001; 58(11):1803-9. DOI: 10.1001/archneur.58.11.1803. View

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View